Life Sciences

  • May 07, 2026

    La. Says Mailed Abortion Pills Harm State Budget, Sovereignty

    The state of Louisiana on Thursday defended its standing to challenge telehealth access to the abortion medication mifepristone, telling the U.S. Supreme Court that it has suffered financial and other injuries as mail-order pills flood the state.

  • May 07, 2026

    Judge, In 'Difficult Position,' OKs Rare Patent Defense

    A Massachusetts federal judge found himself in what he said was a "difficult position" in allowing an unusual defense to be advanced in a patent infringement case related to blood pumps in light of criticism of the defense from the Federal Circuit.

  • May 07, 2026

    $495M Win Upheld In Abbott Baby Formula Bellwether Trial

    A Missouri appellate panel on Tuesday upheld a trial win of $95 million in compensatory damages and $400 million in punitive damages over bellwether claims that Abbott Laboratories' baby formula caused a premature baby to suffer a fully disabling condition.

  • May 07, 2026

    Bayer Sued Over Healthy Sperm Claim On 'One A Day' Pill

    Bayer AG has been hit with a proposed class action in New York federal court alleging that claims on its Men's One A Day Pre-Conception Health Multivitamin supplements misleadingly convey that they could improve chances of conception and support sperm health.

  • May 07, 2026

    Bayer Loses Bid To Undo Class In 'One A Day' Label Suit

    A New York federal judge on Wednesday declined to decertify a class action alleging that Bayer's "One A Day" gummy vitamins deceive consumers about serving sizes, allowing the case to continue since there's evidence that a significant number of consumers could be confused.

  • May 07, 2026

    Liberty Left Client Info Vulnerable To Hackers, Suit Alleges

    Liberty Mutual Insurance Co. faces a proposed consumer class action alleging it failed to effectively safeguard private information for current and former clients after hackers claimed they stole information and sought a ransom payment.

  • May 07, 2026

    Judge Knocks Out Pfizer Partner's Vax Case Against GSK

    A Delaware federal judge on Thursday threw out a suit seeking a finding that a drug developer that partnered with Pfizer and BioNTech on their COVID-19 vaccine didn't infringe drugmaker GlaxoSmithKline's patents.

  • May 07, 2026

    Pharma Cos. Hit With $2M Judgment Over CBD Investor Fraud

    A California federal judge has issued final judgments against a pharmaceutical company, its CEO and an affiliate on claims from the U.S. Securities and Exchange Commission that they defrauded investors of $6.6 million, hitting them with more than $2 million in damages and civil penalties.

  • May 07, 2026

    AstraZeneca Reps Fight To Keep Opt-Ins In Pay Bias Suit

    Female pharmaceutical sales representatives in an AstraZeneca equal pay suit have urged an Illinois federal court to reject the company's bid to dismiss two dozen opt-in plaintiffs for refusing discovery, saying the women feared retaliation and career consequences.

  • May 07, 2026

    Ex‑Novartis Atty Wins Revival Of Whistleblower Claims

    The New Jersey state appeals court on Thursday revived five whistleblower claims brought by a former Novartis compliance attorney, finding that a trial judge wrongly treated a years‑long pattern of alleged retaliation as discrete, time‑barred events rather than a continuous campaign culminating in her 2021 termination.

  • May 07, 2026

    Davis Polk-Led Roche To Pay Up To $1.05B For PathAI

    Davis Polk & Wardwell LLP is advising Roche on a deal announced Thursday that would see the Swiss healthcare company purchase a Boston-based, AI-powered digital pathology company for up to $1.05 billion.

  • May 07, 2026

    King & Spalding Adds Congressional Health Policy Duo In DC

    Two former congressional staffers experienced in health policy recently joined King & Spalding LLP in its Washington, D.C., office, the firm announced this week.

  • May 07, 2026

    Gilead Accuses Pharmacies Of Selling Counterfeit HIV Drugs

    Gilead Sciences has sued several New York City pharmacies claiming they sold counterfeit HIV medication bearing the Gilead brand.

  • May 07, 2026

    Toss Of Ex-Shkreli Atty's Deal May Be Error, 2nd Circ. Hints

    A Second Circuit judge hinted Thursday that a trial judge may have erred in rejecting a retirement-fund garnishment deal that would have protected Martin Shkreli's convicted former lawyer from a potential $1 million "punitive tax event."

  • May 07, 2026

    FBI Assistant GC Joins FBI Alum At Fenwick

    Fenwick & West LLP has hired the former assistant general counsel of the FBI, who will work as a counsel to support technology and life sciences companies and who is rejoining the former FBI director's chief of staff in the Washington, D.C., office.

  • May 06, 2026

    Corcept Must Face Most Teva Mifepristone Antitrust Claims

    A California federal judge on Tuesday once again mostly refused to throw out Teva Pharmaceuticals' claims that Corcept Therapeutics used patent system abuse, bribes and exclusive dealing to block generic competition to its cortisol disorder treatment, finding that at this stage in the litigation the allegations are adequate.

  • May 06, 2026

    J&J, Tolmar Settle Patent Case Over Antipsychotic Drug

    A federal court Wednesday signed off on a consent judgment in a patent case brought by a Johnson & Johnson unit that prevents Tolmar Inc. from selling a generic version of the blockbuster schizophrenia drug Invega Sustenna.

  • May 06, 2026

    'Do Not Use This Report': J&J Hid Asbestos Test, Jury Told

    Johnson & Johnson and a consultant it hired in the 1970s altered the conclusions of tests that found alarming levels of asbestos in the company's talc products before giving different results to the U.S. Food and Drug Administration, a former FDA commissioner told a Los Angeles jury Wednesday.

  • May 06, 2026

    Trulieve Twists Patent Pleading Standard, Cannabis Co. Says

    A cannabis patent holder urged a Florida federal court to reject Trulieve Inc.'s effort to toss an infringement complaint, arguing that proof of its claims isn't needed when initially filing a lawsuit. 

  • May 06, 2026

    Judge Questions OMB Justification For Voiding Grants

    A Massachusetts federal judge on Wednesday pushed back on arguments by the Trump administration that federal agency grants are subject to termination at any time based solely on a change in priorities — a situation, she suggested, that would essentially render any contracts with the government "illusory."

  • May 06, 2026

    Judge Won't Certify Minn. Fraud Question In Cancer Drug MDL

    A New Jersey federal judge won't ask the Supreme Court of Minnesota to weigh in on whether an insurer can pursue claims using a state law typically reserved for the attorney general in litigation alleging drugmaker Celgene used charitable donations to manipulate the price of cancer drugs.

  • May 06, 2026

    Calif. Justices Seem Divided On Gilead HIV Negligence Claim

    The California Supreme Court appeared split Wednesday over whether Gilead should face a negligence claim for allegedly withholding a safer HIV drug from the market to maximize profits from an older drug with more harmful side effects. 

  • May 06, 2026

    9th Circ. Won't Revive Hospital Workers' Vaccine Bias Suit

    The Ninth Circuit refused Wednesday to reopen a religious bias lawsuit accusing a Washington hospital of unlawfully denying employees' requests to avoid a COVID-19 vaccination mandate, finding that the medical center demonstrated that exemptions would've been too burdensome under a 2023 U.S. Supreme Court decision.

  • May 06, 2026

    Alto Says Investors Use Hindsight In Suit Over Drug Trial

    Alto Neuroscience has urged a California federal judge to toss an investor suit alleging the psychiatric biotech company and its top brass overstated the efficacy of their lead drug candidate for treating major depressive disorder, saying the suit is a "classic case of trying to plead fraud by hindsight."

  • May 06, 2026

    CellCentric Closes Latest Funding Round With $220M In Tow

    Clinical-stage biotechnology company CellCentric on Wednesday revealed that it closed its oversubscribed Series D financing round after securing $220 million from investors.

Expert Analysis

  • FDA User Fee Talks Offer Clues On Upcoming Reforms

    Author Photo

    As the U.S. Food and Drug Administration undergoes the User Fee Act reauthorization process and renegotiates its user fee agreements over the next several months, the agency's consultation meetings with relevant industries can shed light on the FDA's priorities, and provides stakeholders an opportunity to participate in the reform process, say attorneys at Holland & Knight.

  • Moderna Case Highlights Overlooked Hurdle In Biopharma IP

    Author Photo

    The recent settlement of the patent litigation involving Moderna's COVID-19 vaccine in Delaware federal court shows that patent portfolios covering enabling platform technologies can create significant freedom-to-operate risk even when their owners are not direct competitors developing the therapeutic product, says Olga Berson at Thompson Coburn.

  • FDA Framework For Personalized Therapies Raises Questions

    Author Photo

    The U.S. Food and Drug Administration's new plausible mechanism framework for developing individualized therapies reflects the agency's focus on rare-disease drugs, but numerous significant, unresolved issues cast uncertainty on how effective the framework will be in practice, say attorneys at Ropes & Gray.

  • Emissions Permits May Not Override Pollution Exclusions

    Author Photo

    Two recent coverage rulings from the Illinois Supreme Court and the Third Circuit suggest a trend among appellate courts to deny coverage under pollution exclusions, even when the emissions happened pursuant to a government permit, say attorneys at Simpson Thacher.

  • 5 Tips For Navigating Your Firm's All-Attorney Summit

    Excerpt from Practical Guidance
    Author Photo

    Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.

  • Series

    Coaching Soccer Makes Me A Better Lawyer

    Author Photo

    Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.

  • Series

    Law School's Missed Lessons: The Human Element

    Author Photo

    Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.

  • Avoid The Unexpected When Drafting License Agreements

    Author Photo

    The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.

  • CMS Healthcare Enforcement Initiatives May Cause Disruption

    Author Photo

    The Centers for Medicare & Medicaid Services' recently announced enforcement actions against healthcare fraud mark a significant escalation, and CMS' prior approach in the hospice sector suggests that even compliant providers and suppliers should brace for impact, say attorneys at Morgan Lewis.

  • The Benefits Of Choosing A Niche Practice In The AI Age

    Author Photo

    As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.

  • How PBMs Can Adapt To Plan Sponsors' Disclosure Demands

    Author Photo

    As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.

  • What New Animal Welfare Enforcement Push Means For Cos.

    Author Photo

    The Trump administration's recently announced multiagency focus on violations of the Animal Welfare Act and related laws will likely lead to broader enforcement actions across industries, heightened scrutiny of compliance standards and a need for businesses to adopt effective risk management practices, says Shennie Patel at Crowell & Moring.

  • How To Engage With Gov't's Direct-To-Consumer Drug Policy

    Author Photo

    The U.S. Department of Health and Human Services' recent request for industry input on manufacturers' direct-to-consumer drug sales reflects the government's caution in this arena, and allows stakeholders a rare opportunity to help shape policy, says Mary Kohler at Kohler Health Law.

  • Series

    Podcasting Makes Me A Better Lawyer

    Author Photo

    Podcasting has changed how I ask questions and connect with people, sharpening my ability to listen without interrupting or prejudging, and bringing me closer to what law is meant to be: a human profession grounded in understanding, judgment and trust, says Donna DiMaggio Berger at Becker.

  • Patent Eligibility Bulletin: Steps To Consider As USPTO Shifts

    Author Photo

    Recent memoranda from the U.S. Patent and Trademark Office, along with some of the first patents issued under Director John Squires, indicate a recalibration of the subject matter eligibility landscape, signaling a renewed emphasis on concrete technological improvements and a potentially pro-AI stance, say attorneys at Banner Witcoff.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.